Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe

Pharmacogenetics

Volumn 7, Issue 4, 1997, Pages 337-340

  Agúndez, José A G ^a   Ramirez, Ronald ^b   Hernandez, Maximo ^b   Llerena, Adrian ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b National Autonomous University of Nicaragua   (Nicaragua)

Author keywords

CYP2D; Cytochrome P450; Gene flow; Hispanics; Nicaraguans

Indexed keywords

CYTOCHROME D; CYTOCHROME P450; DNA FRAGMENT;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NICARAGUA; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HISPANIC AMERICANS; HUMANS; INDIANS, CENTRAL AMERICAN; MALE; NICARAGUA; POLYMORPHISM, GENETIC; SPAIN;

EID: 0030795692     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199708000-00010     Document Type: Article

References (15)

1. Agúndez JAG. Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57. 265-269.
2. Agúndez JAG. Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC. Diaz-Rubio M. Meyer UA, Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid melabolizers. Pharmacogenetics 1996: 6. 501-512.
3. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid melabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996: 278. 441-446.
4. Armstrong M, Fair-brother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994: 4. 73-81.
5. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992: 51. 12-17.
6. Dahl ML, Johansson I, Bertilsson L. Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 264. 516-520.
7. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Agrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6. 193-201.
8. Heim M, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods Enzymol. 1991: 206. 173-183.
9. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90. 11825-11829.
10. Johansson I, Oscarsson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylalion. Mol Pharmacol 1994: 46. 452-459.
11. Jorge LF, Arias TD, Griese U, Nebert DW, Eichelbaum M. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis. Pharmacogenetics 1993: 3. 231-238.
12. Petersen DD, Kong A-NT, Jorge LE, Nebert DW, Arias TD. Debrisoquine polymorphism: novel CYP2D6 gene BamIII restriction fragment length polymorphism in the Ngawbe Guaymi Indian of Panama. Pharmacogenetics 1991: 1. 136-142.
13. Sandy MS, Armstrong M,. Tanner CM, Daly AK, Di Monte DA, Langston JW, Idle JR, CYPT2D6 allelic- frequencies in young-onset Parkinson,s disease. Neurology 1996: 47. 225-230.
14. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991: 1, 26-32.
15. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993: 53. 410-418.